Merck & Company (MRK) Buy, Sell or Hold

Merck & Company (MRK)

147.18

-0.87 (0.59%)

as of Nov 11, 2026, 9:00:00 pm Market Closed.

312 watching

TOP PICK

A quiet stock in that not many people are expecting much from them, 7/8% growth this year but you do get a nice 3%+ dividend yield while you wait. Trades at about 15 X earnings. Has a new cholesterol drug coming out this year.

BUY

Has had problems with patent expiry's and drugs in its channel. Gives a 3% dividend yield. Continues to like.

TOP PICK

trading at significantly less than fair value. Bad news on drug development. Dividends at 3.3%

DON'T BUY

Have had tremendous issues. They had to stop production on a couple of drugs that were being tested. Virtually no revenue or earnings coming.

DON'T BUY

When the stock is not participating in a bull market, steer clear. A strong Company and well financed with good products but there is no real excitement. If the market rolls over, it would get hit hard.

BUY

Likes some of the major pharmaceuticals at these levels. Very cheap. Buy and hold.

STRONG BUY

A fantastic time to be buying this stock. If the pharmaceutical industry reverts to anything near normal, this is a huge screaming buy.

BUY

Missed its numbers. Demographics for drugs looks great. At a great price.

DON'T BUY

Not a fan. They don't have a very strong pipeline of promising drugs. Present drugs are facing competition from generics.

TOP PICK

Trading at a significant discount.Has been getting left behind.

PAST TOP PICK

(Was a top pick on May 21/03. Up 4.4%.) Still likes. Offers good value.

TOP PICK

2.5% dividend. Big name products. Only 14/15 X next years earnings. Recent studies suggest that some of their drugs may also be useful in preventing cancer.

TOP PICK

Trading at 16 X earnings, yielding 2.6%. Great pipeline of new drugs. Great balance sheet.

BUY

Good price. Good earnings price momentum.

TOP PICK

Health care sector is a good sector. 15/16 PE. Good price.

Showing 271 to 285 of 314 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

John Stephenson

Stephenson & Company Capital Management

Christine Poole

Davis Rea

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)